ArticleMolecular therapy. Oncology2026
CAR-T cells directed toward PD-L1 demonstrate potent, antigen-specific activity against cholangiocarcinoma: A proof of concept study.
Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An immunosuppressive microenvironment driven by tumor and stromal cells expressing programmed death-ligand 1 (PD-L1) contributes to immune evasion and poor prognosis in cholangiocarcinoma. Although antibodies to PD-L1 are used clinically, their benefit is limited by immune exclusion within the local microenvironment. To overcome this, we evaluated engineered T cells directed toward PD-L1 that simultaneously target tumor cells and the immunosuppressive microenvironment. Human donor T cells were transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) consisting of an anti-PD-L1 scFv, CD4 transmembrane domain, and 4-1BB/CD3ζ signaling domain. The antitumor efficacy of these CAR-T cells was assessed in a murine orthotopic tumor model, and their specificity and effect were validated in human malignant cholangiocytes with varying PD-L1 expression. PD-L1 CAR-T cells retained T cell identity, demonstrated antigen-specific cytotoxicity, and effectively reduced tumor burden
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.